Gamma‐glutamyl transpeptidase‐to‐platelet ratio is an independent predictor of hepatitis B virus‐related liver cancer

• DOI: 10.1111/jgh.13653
• Publication Date: 2016-11-17T04:10:59Z
• Authors: Yong Eun Park; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang‐Hyub Han; Sojung Han; Mi Young Jeon; Ja Yoon Heo; Kijun Song; Seung Up Kim
• Keywords: Interquartile range; Cumulative incidence

Gamma-glutamyl transpeptidase-to-platelet ratio (GPR) can evaluate the degree of liver fibrosis. We investigated whether GPR predict development hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients.We retrospectively evaluated 1109 CHB patients that were enrolled between 2006 and 2012, all had available data for assessment at enrollment. Three risk groups defined according to tertile stratification: < 0.05, low-risk (n = 370 [33.4%]); 0.05-0.24, intermediate-risk > 0.24, high-risk 369 [33.2%]). The predictive accuracy GPR, fibrosis-4 (FIB-4), aspartate transaminase-to-platelet index (APRI) predicting HCC was tested.The median age study population (746 men 363 women) 50 years. During follow-up period (median, 32 months; interquartile range, 19-57 months), 69 (6.2%) developed HCC. Together with age, male gender, diabetes mellitus, antiviral therapy, serum albumin, alpha-fetoprotein, relative significantly increased from (hazard [HR], up 29.5; adjusted HR, 10.6; P 0.05). In addition, FIB-4 calculated be a high (HR, 20.1; 7.3; 0.05), whereas APRI not (P 0.168). cumulative incidence different among three 0.001, log-rank test).This suggests used as noninvasive marker assess patients.